{
    "Trade/Device Name(s)": [
        "Glucose test system",
        "Glucose"
    ],
    "Submitter Information": "Abbott Laboratories",
    "510(k) Number": "K060383",
    "Predicate Device Reference 510(k) Number(s)": [
        "K953847"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "CFR"
    ],
    "Summary Letter Date": "February 13, 2006",
    "Summary Letter Received Date": "February 22, 2006",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine",
        "Cerebrospinal fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "AEROSET System",
        "ARCHITECT c8000 System",
        "Hitachi 917 Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Hexokinase enzymatic assay",
        "Spectrophotometric detection"
    ],
    "Methodologies": [
        "Enzymatic assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Abbott Laboratories Glucose test system for quantitative measurement of glucose in serum, plasma, urine, or cerebrospinal fluid using hexokinase enzymatic assay",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in blood and other body fluids for diagnosing and treating carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, idiopathic hypoglycemia, and pancreatic islet cell carcinoma",
    "fda_folder": "Clinical Chemistry"
}